This is a partial preview. Full document is 27 slides. View large preview.
EMBED CODE (Copy and Paste)
BENEFITS OF DOCUMENT
In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase over the forecast period, totaling almost $9.5 billion in 2025. This growth will be predominantly fuelled by the approval of seven agents in the indication, and also by Cyramza (Eli Lilly?s ramucirumab).
Got a question about the product? Email us at [email protected] or ask the author directly by using the form to the right. If you cannot view the preview above this document description, go here to view the large preview instead.
Source: Market Overview: Gastric Cancer PowerPoint document
Market Overview: Gastric Cancer
It applies to Healthcare & Life Sciences.
File Size: 2.4 MB
Number of Slides: 27
Purchase includes lifetime product updates. After your purchase, you will receive an email to download this document.
Initial upload date (first version): Mar 8, 2017
Ask the Author a Question
Log In Below
Report this Document
Please explain why the content is inappropriate and provide as much detail as possible. Possible reasons include, but are not limited, to the following:
Are you a business professional?
Just as the mobile apps market has helped software developers earn sustainable, passive income, we hope Flevy will do the same for business professionals, like yourself. There's no reason to let your IP collect dust when it can be making you perpetual income.
CUSTOMERS ALSO BOUGHT THESE DOCUMENTS